Cargando…

Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study

BACKGROUND: Neoadjuvant chemoradiotherapy (NACRT) followed by surgical resection is the standard therapy for locally advanced rectal cancer. However, tumor response following NACRT varies, ranging from pathologic complete response to disease progression. We evaluated the kinases VRK1 and VRK2, which...

Descripción completa

Detalles Bibliográficos
Autores principales:	del Puerto-Nevado, Laura, Marin-Arango, Juan Pablo, Fernandez-Aceñero, Maria Jesus, Arroyo-Manzano, David, Martinez-Useros, Javier, Borrero-Palacios, Aurea, Rodriguez-Remirez, Maria, Cebrian, Arancha, Gomez del Pulgar, Teresa, Cruz-Ramos, Marlid, Carames, Cristina, Lopez-Botet, Begoña, Garcia-Foncillas, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960836/ https://www.ncbi.nlm.nih.gov/pubmed/27456229 http://dx.doi.org/10.1186/s12885-016-2574-9

Ejemplares similares

Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer
por: Gómez del Pulgar, Teresa, et al.
Publicado: (2016)

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2014)

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
por: Martinez-Useros, J., et al.
Publicado: (2018)

Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”
por: Martinez-Useros, J., et al.
Publicado: (2015)

Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
por: Rio-Vilariño, Anxo, et al.
Publicado: (2021)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition
por: Martinez-Useros, Javier, et al.
Publicado: (2019)

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
por: Manzanares-Martin, Barbara, et al.
Publicado: (2021)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer
por: Cenigaonandia-Campillo, Aiora, et al.
Publicado: (2021)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
por: Shields, Julie A., et al.
Publicado: (2022)

Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2
por: Vázquez-Cedeira, Marta, et al.
Publicado: (2011)

VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system
por: So, Jonathan, et al.
Publicado: (2022)

Comparative Interactomes of VRK1 and VRK3 with Their Distinct Roles in the Cell Cycle of Liver Cancer
por: Lee, Namgyu, et al.
Publicado: (2017)

Obesity and colorectal cancer: molecular features of adipose tissue
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer
por: Lacalle-Gonzalez, Carlos, et al.
Publicado: (2023)

Proteomics Identification of Nuclear Ran GTPase as an Inhibitor of Human VRK1 and VRK2 (Vaccinia-related Kinase) Activities
por: Sanz-García, Marta, et al.
Publicado: (2008)

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
por: Cebrián, Arancha, et al.
Publicado: (2017)

Autonomous pick-and-place using the dVRK
por: D’Ettorre, Claudia, et al.
Publicado: (2021)

Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)
por: Hernández Guerrero, Tatiana, et al.
Publicado: (2023)

The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer
por: Li, Weiyao, et al.
Publicado: (2019)

VRK1 Kinase Activity Modulating Histone H4K16 Acetylation Inhibited by SIRT2 and VRK-IN-1
por: Monte-Serrano, Eva, et al.
Publicado: (2023)

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
por: Garcia-Carbonero, Nuria, et al.
Publicado: (2020)

The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance
por: Martinez-Useros, Javier, et al.
Publicado: (2021)

Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments
por: Martinez-Useros, Javier, et al.
Publicado: (2021)

The C/H3 Domain of p300 Is Required to Protect VRK1 and VRK2 from their Downregulation Induced by p53
por: Valbuena, Alberto, et al.
Publicado: (2008)

Functional characterization of lysosomal interaction of Akt with VRK2
por: Hirata, Noriyuki, et al.
Publicado: (2018)

Vrk1 partial Knockdown in Mice Results in Reduced Brain Weight and Mild Motor Dysfunction, and Indicates Neuronal VRK1 Target Pathways
por: Vinograd-Byk, Hadar, et al.
Publicado: (2018)

VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes
por: Martín-Doncel, Elena, et al.
Publicado: (2019)

Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials
por: Ruiz Hispán, Eva, et al.
Publicado: (2021)

The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer
por: Li, Weiyao, et al.
Publicado: (2020)

Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts
por: de la Cueva, Ana, et al.
Publicado: (2013)

VRK-1 extends life span by activation of AMPK via phosphorylation
por: Park, Sangsoon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6tfmquth9sqmmmi3uvhn3n8eh